Solid-State Stability and Polymorph Transformation Studies
Solid-State Stability and Polymorph Transformation Studies
Services
Online Inquiry

Solid-State Stability and Polymorph Transformation Studies

Solid-State Chemistry Services

Systematically characterize polymorphic stability, phase transformations, and solid-form robustness to de-risk drug development.

  • Systematic polymorph screening with high-throughput crystallization technology
  • Salt, co-crystal, and amorphous solid dispersion evaluation
  • Process-relevant stability and transformation studies under controlled conditions

Why Map Solid-State Stability?

Understanding how temperature, humidity, and processing conditions drive polymorph interconversion is critical to ensuring consistent product performance and regulatory compliance.

  • De-risk polymorph-related failures during scale-up
  • Support CMC and patent strategies with robust data
  • Reduce API and drug product variability
Robust
Reliable
Actionable
Our Approach

Integrated Solid-State Investigation

We combine high-throughput experimentation with advanced characterization to map the full polymorph landscape and transformation behavior of your molecule.

Comprehensive Polymorph & Form Screening

Using proprietary high-throughput crystallization and micro-scale techniques, we systematically explore polymorphs, salts, co-crystals, and amorphous forms with minimal material.

  • High-throughput screening with as little as a few grams of API
  • Salt and co-crystal selection ranking for bioavailability
  • Amorphous solid dispersion feasibility evaluation

Stability & Transformation Mechanism Elucidation

We design slurry experiments, stress studies, and process-mimicking conditions to identify metastable forms, transformation pathways, and critical control points.

  • Temperature/humidity cycling and solvent-mediated transformations
  • Kinetic and thermodynamic stability assessment
  • Phase mapping for manufacturing robustness

Analytical Excellence

State-of-the-art techniques including XRPD, DSC, TGA, DVS, NMR, and microscopy ensure unambiguous form identification and purity assessment.

Data-Driven Decisions

All data is compiled into comprehensive reports with clear phase diagrams, transformation schemes, and recommended control strategies.

Regulatory & IP Support

Our studies are designed to meet regulatory expectations for polymorph control and can support patent protection and lifecycle management.

Deliverables

What You Receive

Clearly documented evidence and actionable guidance to advance your solid-state development.

Data & Analytical Reports

  • Full polymorph/salt/co-crystal screening results with XRPD, DSC, TGA, and microscopy data
  • Stability and transformation study reports including phase diagrams
  • Crystallization process development recommendations

Consulting & Regulatory Support

  • Expert interpretation of results and form selection guidance
  • CMC and regulatory documentation support for IND/NDA
  • Confidential study summaries for patent filing
Service Scope

Tailored to Your Stage and Molecule

The scope of each study is defined case-by-case during a detailed consultation, ensuring fit-for-purpose investigation without unnecessary material or cost.

ParameterTypical Project Scope
Solid-form screening (polymorph, salt, co-crystal)Up to 1000+ crystallization experiments using high-throughput technology; scope defined per compound
Stability and transformation studiesSlurry experiments, temperature/humidity cycling, and solvent-mediated transformation; conditions tailored to process
Analytical characterizationXRPD, DSC, TGA, DVS, microscopy; ssNMR or Raman added as needed
Crystallization process developmentSolvent selection, seeding strategy, and critical parameter identification for scale-up
Amorphous solid dispersion evaluationPolymer screening, drug loading, and physical stability assessment
Reporting and data interpretationComprehensive report with phase maps, transformation schemes, and recommendations
Regulatory documentation supportCMC sections, polymorph control strategy, and patent support
Material requirementTypically 2–5 g for full program; mini-screens possible with 100–500 mg
How It Works

Engagement Process

From initial consultation to final report, each project is managed with clear milestones and open communication.

Project Scoping

We discuss your compound, development stage, and specific questions to define the experimental scope, analytical package, and timeline.

Sample Receipt & Preparation

Upon material receipt, we log and prepare samples; stability and storage conditions are confirmed with your team.

High-Throughput Screening & Studies

Our automated platform executes the designed screening and stability experiments while monitoring for transformations.

Data Analysis & Characterization

All solid forms and transformation products are characterized by a suite of analytical techniques; data is compiled into phase diagrams and stability schemes.

Reporting & Recommendations

We deliver a comprehensive report with clear conclusions, recommended form selection, and next-step guidance for development.

Applications

Solid-State Studies Throughout Development

Support from early discovery to commercial manufacturing and lifecycle management.

Identify the Right Solid Form Early

Polymorph and salt screening during lead optimization helps select forms with adequate solubility, stability, and manufacturability for preclinical studies.

  • Salt and polymorph screening for developability assessment
  • Amorphous or co-crystal options for bioavailability enhancement
  • Minimal material requirements for early-stage molecules

De-Risk Process Scale-Up

Stability and transformation studies under process-relevant conditions ensure the selected form remains consistent and robust during scale-up.

  • Process-mimicking slurry and crystallization studies
  • Polymorph interconversion monitoring under temperature/humidity
  • Control strategy definition for manufacturing

Support Filing and Patent Lifecycle

Comprehensive solid-state characterization and stability data are essential for regulatory submissions and can strengthen IP positions.

  • CMC documentation for IND/NDA
  • Polymorph control strategy justification
  • Patent support with novel form screening and characterization
Frequently Asked Questions

Solid-State Stability Studies

Common questions about polymorph transformation investigations and how we approach them.

  • Typical full polymorph screening studies require 2–5 grams of API. For mini-screens or early-stage evaluations, as little as 100–500 mg can be sufficient. The exact amount is confirmed during project scoping based on your molecule and the breadth of the study.

  • Our standard analytical package includes X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapor sorption (DVS). Additional techniques such as solid-state NMR, Raman spectroscopy, and optical microscopy are deployed as needed based on the specific challenges of the compound.

  • Yes, we design transformation studies that simulate key manufacturing steps such as wet granulation, drying, and compression. These studies help identify critical process parameters that influence polymorph stability and are essential for developing a robust control strategy.

  • All experiments are conducted with rigorous quality controls, including reference standards, repeat experiments for key conditions, and independent confirmation of solid forms by multiple analytical techniques. Data are reviewed by senior scientists with extensive experience in solid-state chemistry.

  • Absolutely. Our polymorph screening and stability data are generated in accordance with regulatory expectations for CMC submissions. We can provide CMC-ready documentation, including polymorph control strategies and justification for the selected form, to support IND, NDA, or post-approval changes.

Scientific Literature

References

  1. Iyer J, Barbosa M, Pinto JF, et al. Implications of crystal disorder on the solid-state stability of olanzapine. Journal of pharmaceutical sciences. 2025;114(1):599-616. View on PubMed
  2. Couvrat N, Sanselme M, Poupard M, et al. Solid-State Overview of R-Baclofen: Relative Stability of Forms A, B and C and Characterization of a New Heterosolvate. Journal of pharmaceutical sciences. 2021;110(10):3457-3463. View on PubMed
  3. Zhang Q, Mei XF. [Polymorph transformation of solid drugs]. Yao xue xue bao = Acta pharmaceutica Sinica. 2015;50(5):521-7. View on PubMed

Please kindly note that our products and services are for research use only.